LXRX -
Lexicon Pharmaceuticals, Inc.
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 1.33 0.01 (0.75%) |
0.0 (0.0%) |
0.01 (0.37%) |
0.01 (0.37%) |
0.03 (2.26%) |
0.02 (1.52%) |
0.0 (0.0%) |
0.02 (1.49%) |
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Earnings & Ratios
- Basic EPS:
- 0.01
- Diluted EPS:
- 0.01
- Basic P/E:
- 134.0
- Diluted P/E:
- 134.0
- RSI(14) 1m:
- 62.89
- VWAP:
- 1.34
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
Nov 08, 2025 19:30
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
Sep 22, 2025 20:00
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
Jul 18, 2025 12:00
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst
Mar 31, 2025 09:29
While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60%
Mar 31, 2025 05:25
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Mar 06, 2025 21:00
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
Mar 02, 2025 21:13
George Medicines appoints Amy Carroll as Senior Vice President of Medical Affairs
Feb 03, 2025 12:00
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - Synergistic Rise of Pumps, CGMs, and Ultra-rapid-acting Insulins in T1D Management
Jan 17, 2025 09:53
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
Oct 31, 2024 22:54